ClinicalTrials.gg
CompletedNCT03377361CheckMate 9N9Updated Dec 3, 2025Results posted

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

A Phase 1/2 interventional study of Nivolumab and Trametinib in Colorectal Cancer, Colorectal Tumors and Colorectal Carcinoma, sponsored by Bristol-Myers Squibb. Completed at 47 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing nivolumab in Colorectal Neoplasms — 7 open to participants now, 13 under way, 1 of them phase 3. Nivolumab · Colorectal Neoplasms.

Enrollment
5th of 38
325 · median 49
Started
2018
with 3 others
Phase 1/2
5 of 38
none open now
Registered
7th of 38
by date
Lead sponsor
6 of 38
Bristol-Myers Squibb

Among the 38 studies testing nivolumab in Colorectal Neoplasms, this one is the 5th largest by enrollment, is one of 4 that started in 2018, is one of 5 in phase 1/2, and was the 7th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 38 studies testing nivolumab in Colorectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing nivolumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.

03

Conditions studied

  • Colorectal Cancer
  • Colorectal Tumors
  • Colorectal Carcinoma
  • Colorectal Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed previously treated colorectal cancer with adenocarcinoma histology and in Stage IV per American Joint Committee on Cancer (version 4.0) at study entry
  • Microsatellite status should be performed per local standard of practice, immunohistochemistry (IHC) and/or PCR. If IHC results are equivocal, PCR is required for determining microsatellite stable (MSS) status
  • Must have per 1.1. Participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately
  • (ECOG) Performance Status of 0-1 at screening and on cycle 1 day 1 (C1D1)

Exclusion criteria

Exclusion Criteria:

  • BRAF V600 mutant colorectal cancer
  • Active or
  • Active, known or suspected disease
  • Participants with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study treatment administration
  • History of interstitial lung disease or pneumonitis
  • Prior treatment with and mitogen-activated protein kinase enzymes (MEK) inhibitors
  • History of allergy or to study drug components

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
325 participants (actual)

Study arms

  • Experimental
    Part 1 Cohort 1 3rd Line (3L): nivolumab + trametinib

    Biological: Nivolumab · Drug: Trametinib

  • Experimental
    Part 1A Cohort 2 2nd Line (2L): nivolumab + ipilimumab + trametinib

    Biological: Nivolumab · Drug: Trametinib · Biological: Ipilimumab

  • Experimental
    Part 1A Cohort 3 (2L): nivolumab + ipilimumab + trametinib

    Biological: Nivolumab · Drug: Trametinib · Biological: Ipilimumab

  • Experimental
    Part 2 Cohort 4 (3L): nivolumab + ipilimumab + trametinib

    Biological: Nivolumab · Drug: Trametinib · Biological: Ipilimumab

  • Experimental
    Part 2 Cohort 5 (3L): Regorafenib

    Drug: Regorafenib

  • Experimental
    Part 1B Cohort 6 (2L): nivolumab + ipilimumab + trametinib

    Biological: Nivolumab · Drug: Trametinib · Biological: Ipilimumab

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • Specified dose on specified days

    Also known as: Mekinist

  • BiologicalIpilimumab

    Specified dose on specified days

    Also known as: Yervoy, BMS-734016

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities in Part 1 and Part 1A

    Dose Limiting Toxicities are defined as adverse events have to be at least possibly related to study treatment, and not to disease progression, be clinically relevant and a clinically relevant shift from baseline.

    Time frame: 4 weeks for Doublet Reginmen and 8 weeks for triplet Regimen

  2. Safety Related Events in Part 1 and Part 1 A

    Safety-related events in clinical trials include Adverse Events (AEs), Serious Adverse Events (SAEs), and deaths. An AE is any new or worsening medical issue in a participant receiving the study drug, regardless of its relation to the drug. This includes abnormal lab results, symptoms, or diseases. An SAE is a more severe AE that results in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, involves a birth defect, or is deemed medically important-potentially jeopardizing the participant or requiring intervention, even if not immediately life-threatening. These definitions help ensure consistent reporting and evaluation of safety during clinical studies.

    Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)

  3. Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Thyroid Tests

    Number of participants with clinical laboratory abnormalities in specific thyroid tests

    Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)

  4. Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Liver Tests

    Number of participants with clinical laboratory abnormalities in specific liver tests.

    Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)

  5. Overal Response Rate in Part 1B and Part 2

    ORR is defined as the proportion of all treated participants whose BOR is either confirmed complete response (CR) or confirmed partial response (PR).

    Time frame: Approximately up to 30 Months

Secondary outcomes

  1. Objective Response Rate in Part 1 and Part 1A

    ORR is defined as the proportion of all treated participants whose BOR is either confirmed complete response (CR) or confirmed partial response (PR).

    Time frame: From the first dosing date and the date of the initial objectively documented tumor progression or subsequent therapy date (Approximately up to 21 Months)

  2. Disease Control Rate in Part 1 and Part 1A

    The disease control rate (DCR) is defined as the percentage of participants whose BOR is either confirmed CR or confirmed PR or stable disease (SD)

    Time frame: From the first dosing date and the date of the initial objectively documented tumor progression or subsequent therapy date (Approximately up to 21 Months)

  3. Duration of Response in Part 1 and Part 1A

    DOR for a participant with a BOR of confirmed CR or PR, is defined as the time between the date of first confirmed response and the date of the first objectively documented tumor progression per RECIST 1.1 or death, whichever occurs first.

    Time frame: Approximately up to 20 Months

  4. Time to Response in Part 1 and Part 1A

    Time to response (TTR) is defined for participants who had a confirmed CR or PR as the time from the first dosing date to the date of first documented CR or PR per RECIST 1.1.

    Time frame: From the first dosing date to the date of first documented CR or PR per RECIST 1.1. (Approximately on average 10 months)

  5. Progression Free Survival in Part 1 and Part 1A

    PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression per RECIST 1.1 (ie, radiologic) or death due to any cause, whichever occurs first.

    Time frame: from the first dosing date to the date of first objectively documented disease progression or death, whichever occurs first (Approximately up to 21 months)

  6. Overall Survival in Part 1 and Part 1A

    OS for a participant is defined as the time from the first dosing date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.

    Time frame: Approximately up to 69 Months

  7. Safety Related Events in Part 1B and Part 2

    Safety-related events in clinical trials include Adverse Events (AEs), Serious Adverse Events (SAEs), and deaths. An AE is any new or worsening medical issue in a participant receiving the study drug, regardless of its relation to the drug. This includes abnormal lab results, symptoms, or diseases. An SAE is a more severe AE that results in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, involves a birth defect, or is deemed medically important-potentially jeopardizing the participant or requiring intervention, even if not immediately life-threatening. These definitions help ensure consistent reporting and evaluation of safety during clinical studies.

    Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: 6.8 Months)

  8. Clinical Laboratory Abnormalities in Part 1B and Part 2: Specific Thyroid Tests

    Number of participants with clinical laboratory abnormalities in specific thyroid tests

    Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: 6.8 Months)

  9. Clinical Laboratory Abnormalities in Part 1B and Part 2: Specific Liver Tests

    Number of participants with clinical laboratory abnormalities in specific liver tests.

    Time frame: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: 6.8 Months)

07

Results

Posted Dec 3, 2025

Participant flow

Pre-Treatment
Participant flow — Pre-Treatment
MilestonePart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3BPart 2 Treatment 1Part 2 Treatment 2Part 1B
Started33673371246182
Completed33673371215782
Not completed0000000340
Withdrew: Subject withdrew consent0000000310
Withdrew: Not reported0000000030
Treatment Period
Participant flow — Treatment Period
MilestonePart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3BPart 2 Treatment 1Part 2 Treatment 2Part 1B
Started33673371215782
Completed0000000101
Not completed33673371205781
Withdrew: Disease progression32533361064859
Withdrew: Study drug toxicity00010007216
Withdrew: Death0010000213
Withdrew: Adverse event unrelated to study drug0000001230
Withdrew: Subject request to discontinue study treatment0000000011
Withdrew: Subject withdrew consent0000000021
Withdrew: No longer meets study criteria0100000100
Withdrew: Other reasons0003000201

Outcome measures

PrimaryDose Limiting Toxicities in Part 1 and Part 1A

Dose Limiting Toxicities are defined as adverse events have to be at least possibly related to study treatment, and not to disease progression, be clinically relevant and a clinically relevant shift from baseline.

Time frame:
4 weeks for Doublet Reginmen and 8 weeks for triplet Regimen
Reported as:
Number · Participants
Dose Limiting Toxicities in Part 1 and Part 1A
ParticipantsPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3B
Dose Limiting Toxicities in Part 1 and Part 1A0011000
PrimarySafety Related Events in Part 1 and Part 1 A

Safety-related events in clinical trials include Adverse Events (AEs), Serious Adverse Events (SAEs), and deaths. An AE is any new or worsening medical issue in a participant receiving the study drug, regardless of its relation to the drug. This includes abnormal lab results, symptoms, or diseases. An SAE is a more severe AE that results in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, involves a birth defect, or is deemed medically important-potentially jeopardizing the participant or requiring intervention, even if not immediately life-threatening. These definitions help ensure consistent reporting and evaluation of safety during clinical studies.

Time frame:
Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)
Reported as:
Count of participants · Participants
Safety Related Events in Part 1 and Part 1 A
ParticipantsPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3B
Adverse Events (AEs)3367337
Drug-Related AEs3367337
Serious Adverse Events (SAEs)2043023
Drug-Related SAEs0023011
Deaths2263235
PrimaryClinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Thyroid Tests

Number of participants with clinical laboratory abnormalities in specific thyroid tests

Time frame:
Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)
Reported as:
Count of participants · Participants
Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Thyroid Tests
ParticipantsPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3B
TSH > ULN2113132
TSH > ULN WITH TSH ≤ ULN AT BASELINE2110022
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN2111011
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES ≥ LLN0002121
TSH > ULN WITH FT3/FT4 TEST MISSING0000000
TSH < LLN2022212
TSH <LLN WITH TSH ≥ LLN AT BASELINE1021212
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN2011012
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES ≤ ULN0010200
TSH < LLN WITH FT3/FT4 TEST MISSING0001000
PrimaryClinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Liver Tests

Number of participants with clinical laboratory abnormalities in specific liver tests.

Time frame:
Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)
Reported as:
Count of participants · Participants
Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Liver Tests
ParticipantsPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3B
ALT OR AST > 3XULN0021102
ALT OR AST> 5XULN0021102
ALT OR AST> 10XULN0021002
ALT OR AST > 20XULN0011000
TOTAL BILIRUBIN > 2XULN0020001
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY0020001
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS0020001
PrimaryOveral Response Rate in Part 1B and Part 2

ORR is defined as the proportion of all treated participants whose BOR is either confirmed complete response (CR) or confirmed partial response (PR).

Time frame:
Approximately up to 30 Months
Reported as:
Number · Percentage of Participants
Overal Response Rate in Part 1B and Part 2
Percentage of ParticipantsPart 1BPart 2 Treatment 1Part 2 Treatment 2
Overal Response Rate in Part 1B and Part 29.8 (4.3 to 18.3)1.6 (0.2 to 5.7)1.6 (0.0 to 8.8)
SecondaryObjective Response Rate in Part 1 and Part 1A

ORR is defined as the proportion of all treated participants whose BOR is either confirmed complete response (CR) or confirmed partial response (PR).

Time frame:
From the first dosing date and the date of the initial objectively documented tumor progression or subsequent therapy date (Approximately up to 21 Months)
Reported as:
Number · Percentage of Participants
Objective Response Rate in Part 1 and Part 1A
Percentage of ParticipantsPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3B
Objective Response Rate in Part 1 and Part 1A0 (0.0 to 70.8)0 (0.0 to 70.8)0 (0.0 to 45.9)28.6 (3.7 to 71.0)33.3 (0.8 to 90.6)0 (0.0 to 70.8)0 (0.0 to 41.0)
SecondaryDisease Control Rate in Part 1 and Part 1A

The disease control rate (DCR) is defined as the percentage of participants whose BOR is either confirmed CR or confirmed PR or stable disease (SD)

Time frame:
From the first dosing date and the date of the initial objectively documented tumor progression or subsequent therapy date (Approximately up to 21 Months)
Reported as:
Number · Percentage of Participants
Disease Control Rate in Part 1 and Part 1A
Percentage of ParticipantsPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3B
Disease Control Rate in Part 1 and Part 1A66.7 (9.4 to 99.2)33.3 (0.8 to 90.6)50.0 (11.8 to 88.2)57.1 (18.4 to 90.1)33.3 (0.8 to 90.6)66.7 (9.4 to 99.2)28.6 (3.7 to 71.0)
SecondaryDuration of Response in Part 1 and Part 1A

DOR for a participant with a BOR of confirmed CR or PR, is defined as the time between the date of first confirmed response and the date of the first objectively documented tumor progression per RECIST 1.1 or death, whichever occurs first.

Time frame:
Approximately up to 20 Months
Reported as:
Median · Months
Duration of Response in Part 1 and Part 1A
MonthsPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3B
Duration of Response in Part 1 and Part 1A———9.46 (NA to NA)19.42 (NA to NA)——
SecondaryTime to Response in Part 1 and Part 1A

Time to response (TTR) is defined for participants who had a confirmed CR or PR as the time from the first dosing date to the date of first documented CR or PR per RECIST 1.1.

Time frame:
From the first dosing date to the date of first documented CR or PR per RECIST 1.1. (Approximately on average 10 months)
Reported as:
Median · Months
Time to Response in Part 1 and Part 1A
MonthsPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3B
Time to Response in Part 1 and Part 1A———5.63 (1.8 to 9.5)1.54 (1.54 to 1.54)——
SecondaryProgression Free Survival in Part 1 and Part 1A

PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression per RECIST 1.1 (ie, radiologic) or death due to any cause, whichever occurs first.

Time frame:
from the first dosing date to the date of first objectively documented disease progression or death, whichever occurs first (Approximately up to 21 months)
Reported as:
Median · Months
Progression Free Survival in Part 1 and Part 1A
MonthsPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3B
Progression Free Survival in Part 1 and Part 1A3.58 (1.84 to NA)1.91 (1.74 to NA)2.66 (0.79 to NA)7.36 (1.84 to NA)1.74 (1.74 to NA)4.14 (1.84 to NA)1.81 (0.92 to NA)
SecondaryOverall Survival in Part 1 and Part 1A

OS for a participant is defined as the time from the first dosing date to the date of death due to any cause. A participant who has not died will be censored at last known date alive.

Time frame:
Approximately up to 69 Months
Reported as:
Median · Months
Overall Survival in Part 1 and Part 1A
MonthsPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3B
Overall Survival in Part 1 and Part 1A8.99 (8.80 to NA)18.50 (17.45 to NA)9.61 (0.89 to NA)42.09 (11.60 to NA)19.02 (8.80 to NA)11.33 (10.51 to NA)36.24 (2.23 to NA)
SecondarySafety Related Events in Part 1B and Part 2

Safety-related events in clinical trials include Adverse Events (AEs), Serious Adverse Events (SAEs), and deaths. An AE is any new or worsening medical issue in a participant receiving the study drug, regardless of its relation to the drug. This includes abnormal lab results, symptoms, or diseases. An SAE is a more severe AE that results in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, involves a birth defect, or is deemed medically important-potentially jeopardizing the participant or requiring intervention, even if not immediately life-threatening. These definitions help ensure consistent reporting and evaluation of safety during clinical studies.

Time frame:
Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: 6.8 Months)
Reported as:
Count of participants · Participants
Safety Related Events in Part 1B and Part 2
ParticipantsPart 1BPart 2 Treatment 1Part 2 Treatment 2
Adverse Events (AEs)8212157
Drug-Related AEs8011652
Serious Adverse Events (SAEs)365619
Drug-Related SAEs20213
Deaths4910653
SecondaryClinical Laboratory Abnormalities in Part 1B and Part 2: Specific Thyroid Tests

Number of participants with clinical laboratory abnormalities in specific thyroid tests

Time frame:
Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: 6.8 Months)
Reported as:
Count of participants · Participants
Clinical Laboratory Abnormalities in Part 1B and Part 2: Specific Thyroid Tests
ParticipantsPart 1BPart 2 Treatment 1Part 2 Treatment 2
TSH > ULN133121
TSH > ULN WITH TSH ≤ ULN AT BASELINE91816
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN9143
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES ≥ LLN31314
TSH > ULN WITH FT3/FT4 TEST MISSING144
TSH < LLN14240
TSH <LLN WITH TSH ≥ LLN AT BASELINE11210
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN5120
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES ≤ ULN870
TSH < LLN WITH FT3/FT4 TEST MISSING150
SecondaryClinical Laboratory Abnormalities in Part 1B and Part 2: Specific Liver Tests

Number of participants with clinical laboratory abnormalities in specific liver tests.

Time frame:
Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: 6.8 Months)
Reported as:
Count of participants · Participants
Clinical Laboratory Abnormalities in Part 1B and Part 2: Specific Liver Tests
ParticipantsPart 1BPart 2 Treatment 1Part 2 Treatment 2
ALT OR AST > 3XULN183811
ALT OR AST> 5XULN8198
ALT OR AST> 10XULN154
ALT OR AST > 20XULN032
TOTAL BILIRUBIN > 2XULN3912
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY267
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS277

Adverse events

Collected over Part 1: Approximately 5.5 Months Part 1A: Approximately 6.5 Months Part 1B and 2: Approximately 6.8 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Cohort 12/3 (66.7%)2/3 (66.7%)3/3 (100%)
Part 1 Cohort 1B2/3 (66.7%)0/3 (0%)3/3 (100%)
Part 1 Cohort 1D6/6 (100%)5/6 (83.3%)6/6 (100%)
Part 1A Cohort 23/7 (42.9%)3/7 (42.9%)7/7 (100%)
Part 1A Cohort 2A2/3 (66.7%)0/3 (0%)3/3 (100%)
Part 1A Cohort 33/3 (100%)2/3 (66.7%)3/3 (100%)
Part 1A Cohort 3B5/7 (71.4%)3/7 (42.9%)7/7 (100%)
Part 1B49/82 (59.8%)42/82 (51.2%)82/82 (100%)
Part 2 Treatment 1108/124 (87.1%)79/121 (65.3%)121/121 (100%)
Part 2 Treatment 255/61 (90.2%)33/57 (57.9%)55/57 (96.5%)
Most frequent serious events
Showing 10 of 141
Most frequent serious events
EventPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3BPart 1BPart 2 Treatment 1Part 2 Treatment 2
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/30/60/70/30/30/711/8242/12121/57
HypothyroidismEndocrine disorders0/30/30/60/70/31/30/70/820/1210/57
Abdominal distensionGastrointestinal disorders1/30/30/60/70/30/30/70/820/1210/57
Large intestinal obstructionGastrointestinal disorders0/30/30/60/70/31/30/70/820/1210/57
Infusion related reactionInjury, poisoning and procedural complications0/30/30/60/70/31/30/70/821/1210/57
ArthralgiaMusculoskeletal and connective tissue disorders1/30/30/60/70/30/30/70/820/1210/57
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/30/30/60/70/31/30/70/822/1210/57
PyrexiaGeneral disorders0/30/30/62/70/30/30/75/827/1212/57
Atrial fibrillationCardiac disorders0/30/31/60/70/30/30/70/820/1210/57
ColitisGastrointestinal disorders0/30/31/60/70/30/30/71/822/1210/57
Most frequent other events
Showing 10 of 163
Most frequent other events
EventPart 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3BPart 1BPart 2 Treatment 1Part 2 Treatment 2
DiarrhoeaGastrointestinal disorders3/32/34/66/72/32/34/745/8252/12122/57
NauseaGastrointestinal disorders3/30/32/65/71/32/35/726/8255/1219/57
FatigueGeneral disorders3/31/34/67/73/31/36/733/8251/12122/57
Dermatitis acneiformSkin and subcutaneous tissue disorders2/33/35/64/73/33/36/720/8239/1212/57
AnaemiaBlood and lymphatic system disorders2/30/33/64/71/32/34/718/8236/12112/57
Abdominal distensionGastrointestinal disorders1/30/31/60/72/31/31/72/824/1210/57
Abdominal painGastrointestinal disorders1/30/31/61/72/31/31/718/8217/1219/57
Dry mouthGastrointestinal disorders1/30/30/61/70/32/30/76/827/1215/57
VomitingGastrointestinal disorders1/30/32/62/72/32/32/717/8236/1215/57
ChillsGeneral disorders2/30/30/62/70/31/31/74/829/1211/57

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3BPart 2 Treatment 1Part 2 Treatment 2Part 1BTotal
<=18 years2356236894760223
Between 18 and 65 years101110135142276
>=65 years00000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3BPart 2 Treatment 1Part 2 Treatment 2Part 1BTotal
Female3104213483037129
Male0263124763145170
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3BPart 2 Treatment 1Part 2 Treatment 2Part 1BTotal
Hispanic or Latino0001010106725
Not Hispanic or Latino3366327552751163
Unknown or Not Reported0000000592824111
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 Cohort 1Part 1 Cohort 1BPart 1 Cohort 1DPart 1A Cohort 2Part 1A Cohort 2APart 1A Cohort 3Part 1A Cohort 3BPart 2 Treatment 1Part 2 Treatment 2Part 1BTotal
American Indian or Alaska Native00000000000
Asian001100120510
Native Hawaiian or Other Pacific Islander00000000000
Black or African American00000001113
White33463261195874278
More than one race00000000000
Unknown or Not Reported00100102228
08

Study locations

47 sites
  • Local Institution - 0022
    Birmingham, Alabama 35249, United States
  • Local Institution - 0027
    Los Angeles, California 90033, United States
  • Local Institution - 0067
    Los Angeles, California 90089, United States
  • Local Institution - 0001
    San Francisco, California 94158, United States
  • Local Institution - 0107
    Gainesville, Florida 32610, United States
  • Local Institution - 0111
    Miami, Florida 33136, United States
  • Local Institution - 0028
    Baltimore, Maryland 21287, United States
  • Local Institution - 0116
    Hattiesburg, Mississippi 39401-7233, United States
  • Local Institution - 0103
    St Louis, Missouri 63110, United States
  • Local Institution - 0104
    New York, New York 10016, United States
  • Local Institution - 0029
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0100
    Lancaster, Pennsylvania 17604, United States
  • Local Institution - 0003
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University - Clinical Research Institute
    Philadelphia, Pennsylvania 19107, United States
  • Local Institution - 0101
    Temple, Texas 76508, United States
  • Local Institution - 0002
    Madison, Wisconsin 53792-0001, United States
  • Local Institution - 0120
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
  • Local Institution - 0123
    Buenos Aires, Distrito Federal 1181, Argentina
  • Local Institution - 0122
    Buenos Aires, Distrito Federal C1096AAS, Argentina
  • Local Institution - 0119
    Buenos Aires, 1431, Argentina
  • Local Institution - 0044
    Blacktown, New South Wales 2148, Australia
  • Local Institution - 0043
    Southport, Queensland 4215, Australia
  • Local Institution - 0068
    Elizabeth Vale, South Australia 05112, Australia
  • Local Institution - 0055
    Clayton, Victoria 0, Australia
  • Local Institution - 0069
    Heidelberg, Victoria 3084, Australia
  • Local Institution
    Woluwe-Saint-Lambert, 1200, Belgium
  • Local Institution - 0113
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0070
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0077
    Montreal, Quebec H2X 0A9, Canada
  • Local Institution - 0076
    Ottawa, K1H 8L6, Canada
  • Local Institution - 0117
    Santiago, Santiago Metropolitan 000000, Chile
  • Local Institution - 0118
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0072
    Olomouc, Olomouc Region 779 00, Czechia
  • Local Institution - 0071
    Brno, 65653, Czechia
  • Local Institution - 0073
    Hradec Králové, 500 05, Czechia
  • Local Institution - 0004
    Hanover, 30625, Germany
  • Local Institution - 0095
    Catania, 95124, Italy
  • Local Institution - 0093
    Milan, 20133, Italy
  • Local Institution - 0092
    Padova, 35128, Italy
  • Local Institution - 0094
    Rozzano, 20089, Italy
  • Local Institution - 0079
    Badalona, Barcelona [Barcelona] 08916, Spain
  • Local Institution - 0080
    Pamplona, Navarre 31009, Spain
  • Local Institution - 0052
    Barcelona, 08035, Spain
  • Local Institution - 0114
    Madrid, 28007, Spain
  • Local Institution - 0051
    Madrid, 28041, Spain
  • Local Institution - 0115
    Madrid, 28050, Spain
  • Local Institution - 0096
    Seville, 41013, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Nov 2024, 81 months.

Results were first posted in Dec 2025, 1 year after primary completion.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's 81 months is above that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2017
First posted
Dec 19, 2017
StartActual
Jan 31, 2018
Primary completionActual
Nov 4, 2024
CompletionActual
Nov 4, 2024
Results first posted
Dec 3, 2025
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03377361
Collaborators
Novartis
Responsible party
Sponsor
First posted
Dec 19, 2017
Start date
Jan 31, 2018
Primary completion
Nov 4, 2024
Completion
Nov 4, 2024
Results posted
Dec 3, 2025
Last update
Dec 3, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Trametinib · Ipilimumab · Regorafenib

Start the discussion